Aleks Engel, a Novo partner and Repair Impact Fund director, will work with the firm’s bioindustrial team to accelerate sustainability.

Aleks Engel has joined the bioindustrials division of Novo Holdings, an investment arm of Denmark-based pharmaceutical conglomerate Novo Nordisk.

Aleks Engel
Aleks Engel

Engel’s stint at Novo Holdings began in 2014 when he joined as a director of principal investments. He was promoted to partner at the corporate’s life science investment group, Novo Seeds, four years later.

In his partner role, Engel simultaneously led the company’s $165m fund, Repair Impact Fund, for five years which invests in antimicrobial-resistant treatment developers.

His additional position within the bioindustrials team will enable the corporation to develop green industrial processes that can produce cost-effective products across various sectors, including healthcare.

“Bioindustrials can be simply defined as the use of nature (plants, microorganisms and enzymes) to produce products for the modern industrial society,” Engel said in a LinkedIn post. ” It is an…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Roshini Bains

Roshini Bains is the junior news reporter for Global Corporate Venturing and Global University Venturing.